<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33074186</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2214-3602</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Journal of neuromuscular diseases</Title><ISOAbbreviation>J Neuromuscul Dis</ISOAbbreviation></Journal><ArticleTitle>Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy.</ArticleTitle><Pagination><StartPage>25</StartPage><EndPage>38</EndPage><MedlinePgn>25-38</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JND-200531</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a devastating and incurable motor neuron (MN) disorder affecting both upper and lower MNs. Despite impressive advances in the understanding of the disease's pathological mechanism, classical pharmacological clinical trials failed to provide an efficient cure for ALS over the past twenty years. Two different gene therapy approaches were recently approved for the monogenic disease Spinal muscular atrophy, characterized by degeneration of lower MNs. This milestone suggests that gene therapy-based therapeutic solutions could be effective for the treatment of ALS. This review summarizes the possible reasons for the failure of traditional clinical trials for ALS. It provides then a focus on the advent of gene therapy approaches for hereditary forms of ALS. Specifically, it describes clinical use of antisense oligonucleotides in three familial forms of ALS, caused by mutations in SOD1, C9orf72 and FUS genes, respectively.. Clinical and pre-clinical studies based on AAV-mediated gene therapy approaches for both familial and sporadic ALS cases are presented as well. Overall, this overview highlights the potential of gene therapy as a transforming technology that will have a huge impact on treatment perspective for ALS patients and on the design of future clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cappella</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>INSERM, Institute of Myology, Centre of Research in Myology, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pradat</LastName><ForeName>Pierre-Fran&#xe7;ois</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>INSERM, CNRS, Laboratoire d'Imagerie Biom&#xe9;dicale, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APHP, D&#xe9;partement de Neurologie, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Centre r&#xe9;f&#xe9;rent SLA, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Northern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute Ulster University, C-TRIC, Altnagelvin Hospital, Derry/Londonderry, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Querin</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>INSERM, Institute of Myology, Centre of Research in Myology, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Association Institut de Myologie, Plateforme Essais Cliniques Adultes, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APHP, Service de Neuromyologie, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biferi</LastName><ForeName>Maria Grazia</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>INSERM, Institute of Myology, Centre of Research in Myology, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neuromuscul Dis</MedlineTA><NlmUniqueID>101649948</NlmUniqueID><ISSNLinking>2214-3599</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="Y">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="Y">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AAV</Keyword><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">ASO</Keyword><Keyword MajorTopicYN="N">CNS</Keyword><Keyword MajorTopicYN="N">Gene therapy</Keyword><Keyword MajorTopicYN="N">Intra-CSF delivery</Keyword><Keyword MajorTopicYN="N">MND</Keyword><Keyword MajorTopicYN="N">antisense oligonucleotides</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">miRNA</Keyword><Keyword MajorTopicYN="N">shRNA</Keyword></KeywordList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>19</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33074186</ArticleId><ArticleId IdType="pmc">PMC7902976</ArticleId><ArticleId IdType="doi">10.3233/JND-200531</ArticleId><ArticleId IdType="pii">JND200531</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nature Reviews Neuroscience. 2013;14:248&#x2013;64. 10.1038/nrn3430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3430</ArticleId><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland LP, Shneider NA. Amyotrophic Lateral Sclerosis. New England Journal of Medicine. 2001;344:1688&#x2013;700. 10.1056/NEJM200105313442207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS Clinical Trials Review: 20 Years of Failure. AreWe Any Closer to Registering a New Treatment? Frontiers in Aging Neuroscience. 2017;9. 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits J, Paul P, Jorg C. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology. 2007;68:1571 10.1212/01.wnl.0000260965.20021.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000260965.20021.47</ArticleId><ArticleId IdType="pubmed">17485643</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamez J, Cervera C, Codina A. Flail arm syndrome or VulpianBernhart&#x2019;s form of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 1999;67:258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736499</ArticleId><ArticleId IdType="pubmed">10475767</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Cheng B, Katz IB, Pinto M, Hays AP, Mitsumoto H, et al. The natural history of primary lateral sclerosis. Neurology. 2006;66:647 10.1212/01.wnl.0000200962.94777.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000200962.94777.71</ArticleId><ArticleId IdType="pubmed">16534101</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland LP. Progressive muscular atrophy and other lower motor neuron syndromes of adults. Muscle &amp; Nerve. 2010;41:161&#x2013;5. 10.1002/mus.21565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21565</ArticleId><ArticleId IdType="pubmed">20082312</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Moglia C, Lunetta C, Marinou K, Ticozzi N, Ferrante GD, et al. Factors predicting survival in ALS: A multicenter Italian study. J Neurol. 2017;264:54&#x2013;63. 10.1007/s00415-016-8313-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8313-y</ArticleId><ArticleId IdType="pubmed">27778156</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nature Reviews Neurology. 2014;10:661&#x2013;70. 10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: Nature of impairment and implications for assessment. The Lancet Neurology. 2013;12:368&#x2013;80. 10.1016/S1474-4422(13)70026-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70026-7</ArticleId><ArticleId IdType="pubmed">23518330</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Delgadillo D, Piquard A, Bruneteau G, Pradat P-F, Salachas F, et al. The range and clinical impact of cognitive impairment in French patients with ALS: A cross-sectional study of neuropsychological test performance. Amyotrophic Lateral Sclerosis. 2011;12:372&#x2013;8. 737 10.3109/17482968.2011.580847.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.580847</ArticleId><ArticleId IdType="pubmed">21585273</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6:994&#x2013;1003. 10.1016/S1474-4422(07)70265-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70265-X</ArticleId><ArticleId IdType="pubmed">17945153</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Walsh C, Lynch C, Bede P, Elamin M, Kenna K, et al. Rate of familial amyotrophic lateral sclerosis: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82:623&#x2013;7. 10.1136/jnnp.2010.224501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.224501</ArticleId><ArticleId IdType="pubmed">21047878</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk AE, Weishaupt JH, Andersen PM, Ludolph AC, Kubisch C. Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Med Genet. 2018;30:252&#x2013;8. 10.1007/s11825-018-0185-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11825-018-0185-3</ArticleId><ArticleId IdType="pmc">PMC6132774</ArticleId><ArticleId IdType="pubmed">30220791</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar UG, Milla V, Cynthia Stafford MY, Bjourson AJ, Duddy W, Duguez SM-R. A Systematic Review of Suggested Molecular Strata, Biomarkers and Their Tissue Sources in ALS. Front Neurol. 2019;10. 10.3389/fneur.2019.00400.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00400</ArticleId><ArticleId IdType="pmc">PMC6527847</ArticleId><ArticleId IdType="pubmed">31139131</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Sapp P, O&#x2019;Regan J, McKenna-Yasek D, Schlumpf KS, Haines JL, et al. Genetic linkage analysis of familial amyotrophic lateral sclerosis using human chromosome 21 microsatellite DNA markers. Am J Med Genet. 1994;51:61&#x2013;9. 10.1002/ajmg.1320510114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.1320510114</ArticleId><ArticleId IdType="pubmed">7913294</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Couratier P, Blasco H, Andres CR, Beltran S, Meininger V, et al. Genetics of amyotrophic lateral sclerosis. Rev Neurol (Paris). 2017;173:254&#x2013;62. 10.1016/j.neurol.2017.03.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2017.03.030</ArticleId><ArticleId IdType="pubmed">28449881</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: What do we really know? Nat Rev Neurol. 2011;7:603&#x2013;15. 10.1038/nrneurol.2011.150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.150</ArticleId><ArticleId IdType="pubmed">21989245</ArticleId></ArticleIdList></Reference><Reference><Citation>Marangi G, Traynor BJ. Genetic causes of amyotrophic lateral sclerosis: New genetic analysis methodologies entailing new opportunities and challenges. Brain Res-earch. 2015;1607:75&#x2013;93. 10.1016/j.brainres.2014.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2014.10.009</ArticleId><ArticleId IdType="pmc">PMC5916786</ArticleId><ArticleId IdType="pubmed">25316630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Cleveland DW. Rethinking ALS: The FUS about TDP-43. Cell. 2009;136:1001&#x2013;4. 10.1016/j.cell.2009.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.03.006</ArticleId><ArticleId IdType="pmc">PMC3110083</ArticleId><ArticleId IdType="pubmed">19303844</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron. 2011;72:245&#x2013;56. 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;30. 10.1016/S1474-4422(12)70043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron. 2011;72:257&#x2013;68. 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: A population-based cohort study. Lancet Neurol. 2012;11:232&#x2013;40. 10.1016/S1474-4422(12)70014-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70014-5</ArticleId><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Isaacs AM, Mizielinska S, Mead S, Lashley T, Wray S, et al. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol. 2015;14:291&#x2013;301. 10.1016/S1474-4422(14)70233-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70233-9</ArticleId><ArticleId IdType="pubmed">25638642</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Yu J-T, Zong Y, Zhou J, Tan L. C9ORF72 Mutations in Neurodegenerative Diseases. Mol Neurobiol. 2014;49:386&#x2013;98. 10.1007/s12035-013-8528-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8528-1</ArticleId><ArticleId IdType="pubmed">23934648</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis. New England Journal of Medicine. 1994;330:585&#x2013;91. 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Wobst HJ, Mack KL, Brown DG, Brandon NJ, Shorter J. The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future. Med Res Rev. 2020. 10.1002/med.21661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21661</ArticleId><ArticleId IdType="pmc">PMC7417284</ArticleId><ArticleId IdType="pubmed">32043626</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mazzini L, Mora G. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology. 2020;167:107986 10.1016/j.neuropharm.2020.107986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2020.107986</ArticleId><ArticleId IdType="pubmed">32062193</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Mavel S, Corcia P, Gordon PH. The glutamate hypothesis in ALS: Pathophysiology and drug development. Curr Med Chem. 2014;21:3551&#x2013;75. 10.2174/0929867321666140916120118.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867321666140916120118</ArticleId><ArticleId IdType="pubmed">25245510</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K, Tsuda K, Takahashi F, Palumbo J. Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:64&#x2013;70. 10.1080/21678421.2017.1365372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1365372</ArticleId><ArticleId IdType="pubmed">28872916</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Edaravone: A new drug approved for ALS. Cell. 2017;171:725 10.1016/j.cell.2017.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.10.011</ArticleId><ArticleId IdType="pubmed">29100067</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): A randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12:1059&#x2013;67. 10.1016/S1474-4422(13)70221-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70221-7</ArticleId><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenglet T, Lacomblez L, Abitbol JL, Ludolph A, Mora JS, Robberecht W, et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol. 2014;21:529&#x2013;36. 10.1111/ene.12344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12344</ArticleId><ArticleId IdType="pubmed">24447620</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Atassi N, David W, Cudkowicz M, et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90:e565&#x2013;74. 10.1212/WNL.0000000000004960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004960</ArticleId><ArticleId IdType="pmc">PMC5818014</ArticleId><ArticleId IdType="pubmed">29367439</ArticleId></ArticleIdList></Reference><Reference><Citation>Bella ED, Tramacere I, Antonini G, Borghero G, Capasso M, Caponnetto C, et al. Protein misfolding, amyotrophic lateral sclerosis and guanabenz: Protocol for a phase II RCT with futility design (ProMISe trial). BMJ Open. 2017;7:e015434 10.1136/bmjopen-2016-015434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-015434</ArticleId><ArticleId IdType="pmc">PMC5724081</ArticleId><ArticleId IdType="pubmed">28801400</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, D&#x2019;Amico R, Zucchi E, Gessani A, Fini N, Fasano A, et al. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial). Medicine (Baltimore). 2018;97:e11119 10.1097/MD.0000000000011119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000011119</ArticleId><ArticleId IdType="pmc">PMC6024184</ArticleId><ArticleId IdType="pubmed">29901635</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Crippa V, Cereda C, Bonetto V, Zucchi E, Gessani A, et al. Proteostasis and ALS: Protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS). BMJ Open. 2019;9:e028486 10.1136/bmjopen-2018-028486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-028486</ArticleId><ArticleId IdType="pmc">PMC6549675</ArticleId><ArticleId IdType="pubmed">31152038</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Annals of Neurology. 2006;60:22&#x2013;31. 10.1002/ana.20903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20903</ArticleId><ArticleId IdType="pubmed">16802291</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauria G, Dalla Bella E, Antonini G, Borghero G, Capasso M, Caponnetto C, et al. Erythropoietin in amyotrophic lateral sclerosis: A multicentre, randomised, double blind, placebo controlled, phase III study. J Neurol Neurosurg Psychiatry. 2015;86:879&#x2013;86. 10.1136/jnnp-2014-308996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-308996</ArticleId><ArticleId IdType="pmc">PMC4515982</ArticleId><ArticleId IdType="pubmed">25595151</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, et al. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm. 2015;2. 10.1212/NXI.0000000000000100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000100</ArticleId><ArticleId IdType="pmc">PMC4396529</ArticleId><ArticleId IdType="pubmed">25884010</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, et al. A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis. PLoS One. 2012;7. 10.1371/journal.pone.0037885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0037885</ArticleId><ArticleId IdType="pmc">PMC3371007</ArticleId><ArticleId IdType="pubmed">22715372</ArticleId></ArticleIdList></Reference><Reference><Citation>Patten SA, Aggad D, Martinez J, Tremblay E, Petrillo J, Armstrong GA, et al. Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. JCI Insight. 2017;2. 10.1172/jci.insight.97152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.97152</ArticleId><ArticleId IdType="pmc">PMC5752378</ArticleId><ArticleId IdType="pubmed">29202456</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Cudkowicz ME, Hardiman O, Meng L, Bian A, Lee J, et al. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: Study design and baseline characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:259&#x2013;66. 10.1080/21678421.2018.1426770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1426770</ArticleId><ArticleId IdType="pubmed">29402141</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92:e1610&#x2013;23. 10.1212/WNL.0000000000007242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007242</ArticleId><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Bruijn LI, Shefner JM. ALS drug development guidances and trial guidelines: Consensus and opportunities for alignment. Neurology. 2019;93:66&#x2013;71. 10.1212/WNL.0000000000007695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007695</ArticleId><ArticleId IdType="pmc">PMC6656654</ArticleId><ArticleId IdType="pubmed">31171646</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal NA, Berry JD, Windebank A, Staff NP, Maragakis NJ, van den Berg LH, et al. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle Nerve. 2020. 10.1002/mus.26801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26801</ArticleId><ArticleId IdType="pmc">PMC7496557</ArticleId><ArticleId IdType="pubmed">31899540</ArticleId></ArticleIdList></Reference><Reference><Citation>Kueffner R, Zach N, Bronfeld M, Norel R, Atassi N, Balagurusamy V, et al. Stratification of amyotrophic lateral sclerosis patients: A crowdsourcing approach. Sci Rep. 2019;9:690 10.1038/s41598-018-36873-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-36873-4</ArticleId><ArticleId IdType="pmc">PMC6345935</ArticleId><ArticleId IdType="pubmed">30679616</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89:1915&#x2013;22. 10.1212/WNL.0000000000004606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004606</ArticleId><ArticleId IdType="pmc">PMC5664299</ArticleId><ArticleId IdType="pubmed">28978660</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappella M, Ciotti C, Cohen-Tannoudji M, Biferi MG. Gene Therapy for ALS&#x2014; A Perspective. International Journal of Molecular Sciences. 2019;20:4388 10.3390/ijms20184388.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20184388</ArticleId><ArticleId IdType="pmc">PMC6771059</ArticleId><ArticleId IdType="pubmed">31500113</ArticleId></ArticleIdList></Reference><Reference><Citation>Choong C-J, Baba K, Mochizuki H. Gene therapy for neurological disorders. Expert Opinion on Biological Therapy. 2016;16:143&#x2013;59. 10.1517/14712598.2016.1114096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2016.1114096</ArticleId><ArticleId IdType="pubmed">26642082</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C, Berry JD, McKenna-Yasek DM, Gernoux G, Owegi MA, Pothier LM, et al. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N Engl J Med. 2020;383:151&#x2013;8. 10.1056/NEJMoa2005056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Vita G, Vita GL, Musumeci O, Rodolico C, Messina S. Genetic neuromuscular disorders: Living the era of a therapeutic revolution. Part Diseases of motor neuron and skeletal muscle. Neurol Sci. 2019;40:671&#x2013;81. 10.1007/s10072-019-03764-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-03764-z</ArticleId><ArticleId IdType="pubmed">30805745</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017;377:1723&#x2013;32. 10.1056/NEJMoa947752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa947752</ArticleId><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N Engl J Med. 2018;378:625&#x2013;35. 10.1056/NEJMoa1710504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1710504</ArticleId><ArticleId IdType="pubmed">29443664</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front Neurosci. 2019;13. 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383:109&#x2013;19. 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13&#x2013;21. 10.1016/s0022-510x(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A, et al. Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron. 2016;90:535&#x2013;50. 10.1016/j.neuron.2016.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte A, Lattante S, Zollino M, Marangi G, Luigetti M, Del Grande A, et al. P525L FUS mutation is consistently associated with a severe form of juvenile Amyotrophic Lateral Sclerosis. Neuromuscular Disorders. 2012;22:73&#x2013;5. 10.1016/j.nmd.2011.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2011.08.003</ArticleId><ArticleId IdType="pubmed">21907581</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold C. Tailored treatment for ALS poised to move ahead. Nature Medicine. 2019. 10.1038/d41591-019-00013-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41591-019-00013-w</ArticleId><ArticleId IdType="pubmed">32467611</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study. The Lancet Neurology. 2013;12:435&#x2013;42. 10.1016/S1474-4422(13)70061-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70061-9</ArticleId><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar A-M, et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther. 2009;17:1187&#x2013;96. 10.1038/mt.2009.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2009.71</ArticleId><ArticleId IdType="pmc">PMC2835208</ArticleId><ArticleId IdType="pubmed">19367261</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal-neurons and adult-astrocytes in CNS. Nat Biotechnol. 2009;27:59&#x2013;65. 10.1038/nbt.1515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1515</ArticleId><ArticleId IdType="pmc">PMC2895694</ArticleId><ArticleId IdType="pubmed">19098898</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanguy Y, Biferi MG, Besse A, Astord S, Cohen-Tannoudji M, Marais T, et al. Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice. Front Mol Neurosci. 2015;8:36 10.3389/fnmol.2015.00036.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2015.00036</ArticleId><ArticleId IdType="pmc">PMC4516891</ArticleId><ArticleId IdType="pubmed">26283910</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. New England Journal of Medicine. 2017;377:1713&#x2013;22. 10.1056/NEJMoa1706198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1706198</ArticleId><ArticleId IdType="pubmed">29091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatric Pulmonology. 2019;54:179&#x2013;85. 10.1002/ppul.24203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ppul.24203</ArticleId><ArticleId IdType="pmc">PMC6590370</ArticleId><ArticleId IdType="pubmed">30548438</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Zaidy SA, Kolb SJ, Lowes L, Alfano LN, Shell R, Church KR, et al. AVXS-101 (Onasemnogene Abeparvovec) for SMA Comparative Study with a Prospective Natural History Cohort. Journal of Neuromuscular Disea-ses. 2019;6:307&#x2013;17. 10.3233/JND-190403.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JND-190403</ArticleId><ArticleId IdType="pubmed">31381526</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowes LP, Alfano LN, Arnold WD, Shell R, Prior TW, McColly M, et al. Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy. Pediatric Neurology. 2019;98:39&#x2013;45. 10.1016/j.pediatrneurol.2019.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pediatrneurol.2019.05.005</ArticleId><ArticleId IdType="pubmed">31277975</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer K, Ferraiuolo L, Schmelzer L, Braun L, McGovern V, Likhite S, et al. Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose&#x2013;response Study in Mice and Nonhuman Primates. Mol Ther. 2015;23:477&#x2013;87. 10.1038/mt.2014.210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2014.210</ArticleId><ArticleId IdType="pmc">PMC4351452</ArticleId><ArticleId IdType="pubmed">25358252</ArticleId></ArticleIdList></Reference><Reference><Citation>AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2. Novartis n.d. https://www.novartis.com/news/media-releases/avexis-presents-avxs-101-it-data-demonstrating-remarkable-increases-hfmse-scores-and-consistent-clinically-meaningful-response-older-patients-sma-type-2 (accessed July 15, 2020).</Citation></Reference><Reference><Citation>Foust KD, Salazar DL, Likhite S, Ferraiuolo L, Ditsworth D, Ilieva H, et al. Therapeutic AAV9-mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS. Mol Ther. 2013;21:2148&#x2013;59. 10.1038/mt.2013.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.211</ArticleId><ArticleId IdType="pmc">PMC3863799</ArticleId><ArticleId IdType="pubmed">24008656</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannitti T, Scarrott JM, Likhite S, Coldicott IRP, Lewis KE, Heath PR, et al. Translating SOD1 Gene Silencing toward the Clinic: A Highly Efficacious, Off-Target-free, and Biomarker-Supported Strategy for fALS. Molecular Therapy - Nucleic Acids. 2018;12:75&#x2013;88. 10.1016/j.omtn.2018.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2018.04.015</ArticleId><ArticleId IdType="pmc">PMC6023790</ArticleId><ArticleId IdType="pubmed">30195799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo-Hernandez M, Tadokoro T, Navarro MR, Platoshyn O, Kobayashi Y, Marsala S, et al. Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS. Nat Med. 2020;26:118&#x2013;30. 10.1038/s41591-019-0674-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0674-1</ArticleId><ArticleId IdType="pubmed">31873312</ArticleId></ArticleIdList></Reference><Reference><Citation>AveXis: A Gene Therapy Company. AvexisCom n.d. https://www.avexis.com (accessed July 15, 2020).</Citation></Reference><Reference><Citation>Borel F, Gernoux G, Cardozo B, Metterville JP, Toro Cabreja GC, Song L, et al. Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1G93A Mice and Nonhuman Primates. Hum Gene Ther. 2016;27:19&#x2013;31. 10.1089/hum.2015.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2015.122</ArticleId><ArticleId IdType="pmc">PMC4741242</ArticleId><ArticleId IdType="pubmed">26710998</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F, Gernoux G, Sun H, Stock R, Blackwood M, Brown RH, et al. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci Transl Med. 2018;10. 10.1126/scitranslmed.aau6414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau6414</ArticleId><ArticleId IdType="pubmed">30381409</ArticleId></ArticleIdList></Reference><Reference><Citation>Voyager Therapeutics Announces Preclinical Data for Huntington&#x2019;s Disease and Amyotrophic Lateral Sclerosis Programs at the Congress of the European Society of Gene and Cell Therapy | Voyager Therapeutics Inc. n.d. https://ir.voyagertherapeutics.com/news-releases/news-release-details/voyager-therapeutics-announces-preclinical-data-huntingtons/ (accessed July 15, 2020).</Citation></Reference><Reference><Citation>Biferi MG, Cohen-Tannoudji M, Cappelletto A, Giroux B, Roda M, Astord S, et al. A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model. Mol Ther. 2017;25:2038&#x2013;52. 10.1016/j.ymthe.2017.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.05.017</ArticleId><ArticleId IdType="pmc">PMC5589057</ArticleId><ArticleId IdType="pubmed">28663100</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R, Liefhebber JM, Garc&#xed;a-Osta A, Miniarikova J, Cuadrado-Tejedor M, Espelosin M, et al. Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. Molecular Therapy - Nucleic Acids. 2019;16:26&#x2013;37. 10.1016/j.omtn.2019.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.02.001</ArticleId><ArticleId IdType="pmc">PMC6393708</ArticleId><ArticleId IdType="pubmed">30825670</ArticleId></ArticleIdList></Reference><Reference><Citation>Armbruster N, Lattanzi A, Jeavons M, Van Wittenberghe L, Gjata B, Marais T, et al. Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy. Molecular Therapy - Methods &amp; Clinical Development. 2016;3:16060 10.1038/mtm.2016.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtm.2016.60</ArticleId><ArticleId IdType="pmc">PMC5022869</ArticleId><ArticleId IdType="pubmed">27652289</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevan AK, Duque S, Foust KD, Morales PR, Braun L, Schmelzer L, et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther. 2011;19:1971&#x2013;80. 10.1038/mt.2011.157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2011.157</ArticleId><ArticleId IdType="pmc">PMC3222525</ArticleId><ArticleId IdType="pubmed">21811247</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinderer C, Bell P, Katz N, Vite CH, Louboutin J-P, Bote E, et al. Evaluation of Intrathecal Routes of Administration for Adeno-Associated Viral Vectors in Large Animals. Hum Gene Ther. 2018;29:15&#x2013;24. 10.1089/hum.2017.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2017.026</ArticleId><ArticleId IdType="pmc">PMC5770082</ArticleId><ArticleId IdType="pubmed">28806897</ArticleId></ArticleIdList></Reference><Reference><Citation>Samaranch L, Salegio EA, San Sebastian W, Kells AP, Foust KD, Bringas JR, et al. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther. 2012;23:382&#x2013;9. 10.1089/hum.2011.200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2011.200</ArticleId><ArticleId IdType="pmc">PMC3327605</ArticleId><ArticleId IdType="pubmed">22201473</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Liu C, Yang C, Wang D, Wu D, Qi Y, et al. Slow intrathecal injection of rAAVrh10 enhances its transduction of spinal cord and therapeutic efficacy in a mutant SOD1 model of ALS. Neuroscience. 2017;365:192&#x2013;205. 10.1016/j.neuroscience.2017.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2017.10.001</ArticleId><ArticleId IdType="pmc">PMC5757625</ArticleId><ArticleId IdType="pubmed">29024785</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeler AM, Zieger M, Semple C, Pucci L, Veinbachs A, Brown RH, et al. Intralingual and Intrapleural AAV Gene Therapy Prolongs Survival in a SOD1 ALS Mouse Model. Mol Ther Methods Clin Dev. 2019;17:246&#x2013;57. 10.1016/j.omtm.2019.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2019.12.007</ArticleId><ArticleId IdType="pmc">PMC6962641</ArticleId><ArticleId IdType="pubmed">31970202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu H-L, Brown A, Loveland AB, Lotun A, Xu M, Luo L, et al. Structural characterization of a novel human adeno-associated virus capsid with neurotropic properties. Nature Communications. 2020;11:3279 10.1038/s41467-020-17047-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17047-1</ArticleId><ArticleId IdType="pmc">PMC7327033</ArticleId><ArticleId IdType="pubmed">32606306</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, Mingozzi F, et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood. 2012;119:3038&#x2013;41. 10.1182/blood-2011-09-382317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-09-382317</ArticleId><ArticleId IdType="pmc">PMC3321866</ArticleId><ArticleId IdType="pubmed">22271447</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathwani AC, Reiss UM, Tuddenham EGD, Rosales C, Chowdary P, McIntosh J, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371:1994&#x2013;2004. 10.1056/NEJMoa1407309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1407309</ArticleId><ArticleId IdType="pmc">PMC4278802</ArticleId><ArticleId IdType="pubmed">25409372</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathwani AC, Reiss U, Tuddenham E, Chowdary P, McIntosh J, Riddell A, et al. Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing Empty Viral Particles on Safety and Efficacy of Gene Transfer. Blood. 2018;132:491&#x2013;491. 10.1182/blood-2018-99-118334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-99-118334</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilbaud M, Devaux M, Couzini&#xe9; C, Le Duff J, Toromanoff A, Vandamme C, et al. Five Years of Successful Inducible Transgene Expression Following Locoregional Adeno-Associated Virus Delivery in Nonhuman Primates with No Detectable Immunity. Hum Gene Ther. 2019;30:802&#x2013;13. 10.1089/hum.2018.234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2018.234</ArticleId><ArticleId IdType="pmc">PMC6648187</ArticleId><ArticleId IdType="pubmed">30808235</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouel F, Rolland A-S, Devedjian J-C, Burnouf T, Devos D. Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates. Front Neurol. 2019;10:835 10.3389/fneur.2019.00835.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00835</ArticleId><ArticleId IdType="pmc">PMC6688198</ArticleId><ArticleId IdType="pubmed">31428042</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi S, Thammisetty SS, Codron P, Rahimian R, Plourde KV, Soucy G, et al. Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology. J Clin Invest. 2019;129:1581&#x2013;95. 10.1172/JCI123931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI123931</ArticleId><ArticleId IdType="pmc">PMC6436898</ArticleId><ArticleId IdType="pubmed">30667370</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Chapter One - Functional Significance of TDP-43 Mutations in Disease. In: Friedmann T, Dunlap JC, Goodwin SF, editors. Advances in Genetics, vol. 91, Academic Press; 2015, pp. 1-53. 10.1016/bs.adgen.2015.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.adgen.2015.07.001</ArticleId><ArticleId IdType="pubmed">26410029</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, Halliday GM, Kril JJ, Ittner LM, G&#xf6;tz J, Kiernan MC, et al. The frontotemporal dementia-motor neuron disease continuum. The Lancet. 2016;388:919&#x2013;31. 10.1016/S0140-6736(16)00737-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00737-6</ArticleId><ArticleId IdType="pubmed">26987909</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross SK, Shim BS, Bartus RT, Deaver D, McEachin Z, B&#xe9;tourn&#xe9; A, et al. Focal and dose-dependent neuroprotection in ALS mice following AAV2-neurturin delivery. Experimental Neurology. 2020;323:113091 10.1016/j.expneurol.2019.113091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2019.113091</ArticleId><ArticleId IdType="pubmed">31678350</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasiene J, Komine O, Fujimori-Tonou N, Powers B, Endo F, Watanabe S, et al. Neuregulin 1 confers neuroprotection in SOD1-linked amyotrophic lateral sclerosis mice via restoration of C-boutons of spinal motor neurons. Acta Neuropathol Commun. 2016;4. 10.1186/s40478-016-0286-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0286-7</ArticleId><ArticleId IdType="pmc">PMC4758105</ArticleId><ArticleId IdType="pubmed">26891847</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf2;dol-Caballero G, Herrando-Grabulosa M, Garc&#xed;a-Lareu B, Solanes N, Verd&#xe9;s S, Osta R, et al. Gene therapy for overexpressing Neuregulin 1 type I in skeletal muscles promotes functional improvement in the SOD1G93A ALS mice. Neurobiol Dis. 2020;137:104793 10.1016/j.nbd.2020.104793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.104793</ArticleId><ArticleId IdType="pubmed">32032731</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature. 2004;429:413 10.1038/nature02544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02544</ArticleId><ArticleId IdType="pubmed">15164063</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC, Treleaven CM, Fidler JA, Hester M, Haidet A, Handy C, et al. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol Ther. 2010;18:2075&#x2013;84. 10.1038/mt.2010.206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2010.206</ArticleId><ArticleId IdType="pmc">PMC2997594</ArticleId><ArticleId IdType="pubmed">20859261</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar BK, Llad&#xf3; J, Sherkat N, Rothstein JD, Gage FH. Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model. Science. 2003;301:839&#x2013;42. 10.1126/science.1086137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1086137</ArticleId><ArticleId IdType="pubmed">12907804</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore AC, Haenggeli C, Gasmi M, Bishop KM, Bartus RT, Maragakis NJ, et al. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res. 2016;19:256&#x2013;65. 10.1016/j.brainres.2007.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.09.034</ArticleId><ArticleId IdType="pmc">PMC2265207</ArticleId><ArticleId IdType="pubmed">17963733</ArticleId></ArticleIdList></Reference><Reference><Citation>Khademullah CS, Aqrabawi AJ, Place KM, Dargaei Z, Liang X, Pressey JC, et al. Cortical interneuron-mediated inhibition delays the onset of amyotrophic lateral sclerosis. Brain. 2020;143:800&#x2013;10. 10.1093/brain/awaa034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa034</ArticleId><ArticleId IdType="pubmed">32203578</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P, Nicholson GA, Ng K, Howells J, Kril JJ, et al. Cortical Function in Asymptomatic Carriers and Patients With C9orf72 Amyotrophic Lateral Sclerosis. JAMA Neurol. 2015;72:1268&#x2013;74. 10.1001/jamaneurol.2015.1872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.1872</ArticleId><ArticleId IdType="pmc">PMC4707047</ArticleId><ArticleId IdType="pubmed">26348842</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Zhang L, Liang B, Schroeder D, Zhang Z-W, Cox GA, et al. Hyperactive somatostatin interneurons contribute to excitotoxicity in neurodegenerative disorders. Nat Neurosci. 2016;19:557&#x2013;9. 10.1038/nn.4257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4257</ArticleId><ArticleId IdType="pmc">PMC4811704</ArticleId><ArticleId IdType="pubmed">26900927</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, Debray TPA, Visser AE, Eijk RPA van, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: Development and validation of a personalised prediction model. The Lancet Neurology. 2018;17:423&#x2013;33. 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>